Fulcrum Therapeutics, Inc.
fulcrumtx.comWhat Do They Do?
Develops small-molecule drug candidates for patients with genetically defined rare diseases, including sickle cell disease.
10-K for FY2025, filed Feb 24, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 30, 2026
−$26.2MView ↗
- ▲ +51% (Loss)
- vs −$17.3M in Q2 FY2025
-
Aug 17, 2026
Agreed to merge with Slate Medicines
The combined company is expected to focus on Slate’s migraine pipeline; closing is expected in the fourth quarter of 2026.
Sources
8-K, filed Aug 17, 2026
On August 16, 2026, Fulcrum Therapeutics, Inc., a Delaware corporation (“Fulcrum”) entered into an Agreement and Plan of Merger (the…View ↗
-
Jun 1, 2026
Discontinued pociredir for sickle cell disease
The company also began a review of strategic alternatives after FDA feedback left no viable regulatory path for further clinical development.
Sources
8-K, filed Jun 1, 2026
On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA. The minutes reflected heightened FDA…View ↗
-
Apr 27, 2026
CFO Alan Musso announced plans to retire
Sources
8-K, filed Apr 27, 2026
Retirement of Chief Financial OfficerView ↗
Product focus
The older report described losmapimod for FSHD and another candidate for SCD; the latest centers its overview on pociredir for SCD.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 24, 2026We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in…View ↗
Our most advanced product candidate, losmapimod, is a small molecule that we in-licensed from affiliates of GlaxoSmithKline plc, or GSK…View ↗
Our other product candidate, FTX-6058, is an investigational oral fetal hemoglobin, or HbF, inducer that is in development for the…View ↗
Discovery emphasis
The older report described discovery efforts across muscular, hematologic and neurologic disorders; the latest names hematology as the primary focus and also describes a preclinical prostate cancer candidate.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 24, 2026According to the National Institutes of Health, or NIH, there are approximately 7,000 rare, genetically defined human diseases, many of…View ↗
Who Do They Compete With?
Competes with Bristol-Myers Squibb, Norgine, Novartis, Emmaus Life Sciences, Genetix Biotherapeutics, Vertex Pharmaceuticals, Pfizer, Novo Nordisk, GSK, Cellarity, Agios Pharmaceuticals, Sanofi, and Beam Therapeutics
10-K for FY2025, filed Feb 24, 2026Several approved therapies for SCD are intended to reduce VOCs or other complications of SCD. The five drug treatments approved in the…View ↗
Loading...
